Docs may find stellar Gilead/Bristol-Myers hep C combo too good to ignore

John Carroll   What if you had a great combination of rival drugs that worked in 100% of patients but one of the companies involved refused to participate in the trials needed ...

Symonds steps down as Novartis CFO, Kirsch takes over

Alok Saboo Welcome to this week’s roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) ...

Europeans throw cold water on Pfizer’s hot streak with Xeljanz rejection

Ryan McBride European authorities have battered expectations for Pfizer's rheumatoid arthritis pill Xeljanz, spurning the drug giant's request for approval over concerns about ...

Johnson & Johnson, Evotec bask in Harvard’s breaking diabetes discovery

Ryan McBride The German biotech Evotec and Johnson & Johnson ($ JNJ) have the inside track on drug development based on a Harvard lab's discovery of a hormone that spurs replication ...

Guidelines for contributing an Industry Voices column to Fierce

Arsalan Arif Industry Voices is a platform for life sciences professionals to provide their particular view of a current technology, industry, or business topic.  Its goal is ...

Docs call drugmakers ‘profiteers’ for costs of cancer meds

Eric Palmer Sanofi ($ SNY) is not very popular among its peers today. Its decision last year to halve the cost of its colon cancer drug Zaltrap in the face of high-profile criticism ...

Biotech startup hustles new Alzheimer’s program to the clinic

John Carroll Back in early 2012, a number of physicians around the U.S. began fielding some unusual requests from Alzheimer's patients for a prescription covering Targretin (bexarotene), ...

Actavis to make generic tamper-resistant OxyContin

Eric Palmer Purdue Pharma and generic drugmaker Actavis ($ ACT) have settled their patent suit over a special formulation of the painkiller OxyContin just 10 days the FDA banned generic ...

Fierce at BIO 2013 in Chicago

Alok Saboo CHICAGO–Editors from FierceBiotech and FierceMedicalDevices were on hand to chat with executives who made the trek to BIO’s 2013 International Convention in ...

Sanofi distances itself from consultant caught up in tax fraud probe

Eric Palmer Sanofi ($ SNY), already facing intense criticism for job cuts in France, now finds itself defending the use of a lobbyist who was a consultant to CEO Chris Viehbacher. ...

Biotech Receptos trots out terms for $71M IPO

Ryan McBride San Diego-based Receptos, which made known its plans to go public weeks ago, has proposed a price range of $ 14 to $ 16 in the sale of 4.7 million shares, according ...

NIH stops HIV vaccine trial after immunizations fail

Emily Mullin The federal government has put the brakes on the largest and most advanced study of a vaccine against HIV infection after an independent data and safety monitoring board ...
Page 3 of 1712345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS